Global Point Of Care
実際に毎年、アボットだけでも 10 億を超える検査製品を世界全体に提供しています。
たとえば、POC 製品による検査を受けた HIV 患者の抗レトロウイルス療法 (ART) 開始は、研究機関の補助を必要とする従来の方法で診断された患者に比べて 130 日早かったと報告されています1。
改善例: POC 検査を受けた心不全患者の退院は、POC 検査を受けなかった患者に比べて 3 日早く、経済面と健康面の両方で良好な結果が得られています。2
皆さまが直面している問題も含め、世界中で直面している重大な保健医療上の問題をアボットの診断検査ソリューションがどのように解決できるかをご覧ください。
A Leader In Rapid Point-of-care Diagnostics.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement | Declaration for California Compliance Law.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.